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The biology of the alpha subunits of 
Hypoxia Inducible Factors (HIFα) has 
expanded from their role in angiogenesis to 
their current position in the self-renewal 
and differentiation of stem cells. The results 
reported in this paper show the discovery of 
FM19G11, a novel chemical entity that 
inhibits the HIFα proteins that repress the 
target genes of the two α subunits, in 
various tumor cell lines as well as in adult 
and embryonic stem cell (ESC) models 
from rodents and humans, respectively. 
FM19G11 inhibits at nanomolar range the 
transcriptional and protein expression of 
Oct4, Sox2, Nanog and Tgf-
α undifferentiating factors, in adult rat and 
human ESC. FM19G11 activity occurs in 
ependymal progenitor stem cells from rats 
(epSPC) - a cell model reported for spinal 
cord regeneration. That it allows the 
progression of oligodendrocyte cell 
differentiation in a hypoxic environment 
has created interest in its characterization 
for pharmacological research. Experiments 
using siRNA showed a significant depletion 
in Sox2 protein only in the case of HIF2α 
silencing, but not in HIF1α−mediated 
ablation. Moreover, ChIP data, together 
with the significant presence of functional 
hypoxia response element consensus 
sequences (HREs) in the promoter region of 
Sox2, strongly validated that this factor 
behaves as a target gene of HIF2α in 
epSPCs. FM19G11 causes a reduction of 
overall histone acetylation with significant 
repression of p300, a histone acetyl 
transferase required as a co-factor for HIF-
transcription activation. Arrays carried out 
in the presence and absence of the inhibitor 
showed the predominant involvement of 
epigenetic–associated events mediated by 
the drug.  
 
INTRODUCTION 
Hypoxia-inducible transcription factors 
(HIFs) have been the subject of numerous 
research studies, as they are the key 
regulators of cell reaction to the lack of cell 
oxygen. They are widely referred to, in the 
context of pathological processes of cancer, 
inflammation, cardiovascular and 
neurodegenerative diseases and, in general, 
all the angiogenic pathologies (reviewed in 
(1-4)). More recently, HIF biology has 
stretched due to its interactions with cell 
pathways that regulate stem cell self-
renewal and differentiation, suggesting a 
new mechanism whereby HIF proteins may 
drive tumor growth through the generation 
of tumor-initiating cells or cancer stem cells 
(5,6). HIFα proteins, a hallmark of different 
tumor types, were the focus of many drug 
discovery efforts, but most inhibitors did 
not comply with the pharmacological 
properties required for approval of the drug 
by the regulatory agencies. Thus, even after 
more than 20 years of research, there is still 
room for intervention with novel small 
molecules that modulate HIF. Strategies for 
HIF inhibitors include the wide area of 
angiogenic pathologies and, within the field 
of regenerative medicine, the promising 
treatments for degenerative diseases and/or 
the pre-conditioning of the stem cells used 
for cell transplantation therapies.  
HIF is a heterodimer consisting of an 
oxygen-regulated α subunit (1α, 2α or 3α) 
and a constitutively expressed β subunit, or 
ARNT. HIF proteins are members of the 
bHLH-PAS family and bind to canonical 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M109.008326The latest version is at 
JBC Papers in Press. Published on November 6, 2009 as Manuscript M109.008326
 Copyright 2009 by The American Society for Biochemistry and Molecular Biology, Inc.
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 22, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 2
DNA sequences (hypoxia-regulated 
elements or HREs) in the promoters or 
enhancers of target genes. Despite the 
existing similarities, α subunits trigger 
overlapping and specific genes and are 
therefore involved in different molecular 
pathways with different physiological 
consequences for the cells with non-
redundant or compensatory function (7-9). 
Briefly, HIF1α, but not HIF2α,  induces 
genes involved in the glycolysis process 
(10), whereas HIF2α regulates the 
angiogenic route, even in the absence of 
hypoxia (11). HIF2α is also seen as the 
physiological regulator of Epo production 
in adult mice (12).  HIF3α, however, forms 
an abortive transcriptional complex with 
HIF-2 α and prevents the engagement of 
HIF-2 with the hypoxia-responsive 
elements (HREs) acting as negative 
feedback regulators (13). HIF activity is 
mainly regulated at protein level, due to the 
hydroxylation of the key proline residues 
present in the oxygen-dependent 
degradation domain (ODD) of the α 
subunits by the prolyl-hydroxylases (PHDs) 
triggering polyubiquitination and rapid 
degradation of the HIFα proteins through 
an E3 ubiquitin ligase complex (14). 
Depletion of oxygen prevents destruction, 
leading to stabilized α proteins that interact 
with ARNT in the nucleus, recognize the 
HRE sequences in the DNA and activate 
the transcription mediated by the p300/CBP 
complexes.  
HIFα proteins affect the self-renewal and 
the differentiation processes of stem cells 
by specific regulation of relevant genes and 
the key transcription factors involved in 
these processes. It is now known that 
lowered oxygen concentration enhances 
neurogenesis and delays certain 
differentiation processes (15,16). For 
instance, HIF1α interacts with Notch1 to 
maintain undifferentiated cell states (5), 
whereas HIF2α binds to the marker of the 
undifferentiated state Oct4 promoter, 
inducing its expression and transcriptional 
activity (8). Sox2 controls pluripotency by 
direct modulation of Oct4 levels in 
embryonic stem cells of mice (17,18). 
Recent papers have shown how 
pluripotency can be acquired through only a 
few genetic modifications. Interestingly, the 
experiments of Takahashi et al. showed that 
somatic cells can be reprogrammed into 
pluripotent stem cells by transduction of 
four defined transcription factors, c-Myc, 
KLF4, Sox2 and Oct4 (19,20), two of 
which (Oct4 and c-Myc) are directly 
activated by HIF2α (8,21).  
One of the most challenging objectives in 
cell therapy is to restore neurological 
function after spinal cord injury (SCI). 
After SCI, there is a significant cell 
proliferation of ependymal-derived 
stem/progenitor cells (epSPC) (22). It is 
possible to restore locomotor activity when 
epSPC, activated by the injured tissue 
(epSPCi), are ectopically transplanted (23).  
Altering the fate of engrafted or 
endogenous epSPCi, to restrict 
differentiation to oligodendrocytes or a 
neuronal lineage, would replace the loss of 
functional units and would delay the 
demyelination process (23). In the present 
study, we identified and characterized a 
new chemical entity, FM19G11, which 
inhibits the expression and transcriptional 
activity of HIFα isoforms and their 
corresponding target genes, including the 
HIF2α-mediated regulation of Sox2, newly 
characterized here. The specific inhibition 
of HIFα proteins by FM19G11 reduces the 
transcriptional activation of the expression 
of the pluripotency markers Sox2 and Oct4 
and the corresponding target genes TGFα 
and Nanog in epSPC, thus driving cell 
differentiation to oligodendrocytes in a 
process that may favor the design of 
pharmacological strategies for spinal cord 
regeneration.  
 
EXPERIMENTAL PROCEDURES 
Plasmids and treatments 
The plasmid 9x-HRE-Luc with a luciferase 
reporter gene was kindly provided by Dr.  
MO Landazuri. This plasmid containing the 
neomycin resistance gene was used to 
generate a stably transduced HeLa cell line 
(HeLa-9x). Plasmids pCMV-TRE and 
pGL2-CRE containing a firefly luciferase 
gene, and the plasmids containing the 
cDNAs of ATF2, JunB, c-fos and c-jun, 
kindly provided by Dr. R. Farrás, were used 
for stable and transient transfection in the 
HEK293T cell line (the 293-TRE and 293-
CRE cell lines were created). 
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For Sox2 promoter transcriptional activity 
analysis, a reporter construct was created in 
pGL3-basic, including the region of mouse 
Sox2 promoter sequence -392/-1725 
upstream of start codon (pGL3-mpSox2). 
The in silico search of HRE sequences in 
the mouse sequence showed the presence of 
two sites, -725 and -1320, and both were 
point-mutated by PCR (mpSox2Δ) using 
the following primers: -1320 HRE FW:  
CCTATTTGTAACGGAAATGGGGCTGT
GGCTC, RV_5' 
GAGCCACAGCCCCATTTCCGTTACAA
ATAGG; -725 HRE FW_5´ 
GAATTAGGGGTTGAGGACAAATGCT
GCGGTTCCTTGAGC and RV_ 
GCTCAAGGAACCGCAGCATTTGTCCT
CAACCCCTAATTC.Luciferase reporter 
activity assays 
105 HEK293T, HeLa-9x, 293-TRE or 293-
CRE cells per well were seeded onto white 
96-well plates in quadruplicate 24 hours 
prior to assay. For transient over-
expression, 0.05 ug/well in 96-well plates 
of each plasmid, ATF-2, JunB, c-jun, c-fos, 
PGL3-basic, pGL3-mpSox2, pGL3 and 
mpSox2Δ, were transfected with FuGene6 
HD (3:6) 24 hours before stimulation. 
Serial dilutions of FM19G11 from 0 
(containing DMSO as a control) up to 1 µM 
were added immediately before hypoxic 
stimulation in 1% O2 atmospheres created 
by the In vivo2 400 chamber (Ruskinn Life 
Sciences, USA). 6 hrs after stimulation, 
luciferase activity was quantified by 
addition of an equal volume of Bright-Glo 
Luciferase Reagent (Promega, USA) and 
detected in the VICTOR3 luminometer 
(Perkin Elmer, USA). 
Cytotoxicity assay 
Cell viability was measured by following 
the CellTiter 96®Aqueous Non-
Radioactive Cell Proliferation Assay 
instructions (Promega, USA).  5x104 HeLa 
cells per well were seeded onto 96-well 
plates 24 hours before assay. Serial 
dilutions of FM19G11 from 0 (containing 
DMSO as a control) up to 100 µM were 
used to stimulate the cells for 72 hours 
under standard oxygen conditions (∼20% 
O2) or hypoxic atmosphere (1% O2).  
Chemical synthesis of FM19G11   
The detailed protocols for the synthesis of 
FM19G11 and its precursors are included in 
Supplementary data I. 
Ependymal/progenitor cell isolation and 
culture  
epSPC were harvested from adult  female 
Sprague Dawley rats (~200 g), isolated and 
cultured as described elsewhere (23).  
Oligodendrocyte-directed differentiation: 
Differentiation was performed as previously 
described (23). Briefly, epSPCs were 
cultured with glial restriction media 
(GRM): DMEM:F12, B27 supplement 
(Invitrogen, CA), 25 µg/ml insulin, 6.3 
ng/ml progesterone, 10 µg/ml putrescine, 
50 ng/ml sodium selenite, 50 µg/ml 
holotransferin, 40 ng/ml tri-iodo-thyroidin, 
supplemented with 4 ng/ml bFGF and 10 
ng/ml EGF (Sigma, MO) for one day. 
Subsequently, cells were incubated with 20 
ng/ml EGF and 10 µM of all-trans retinoic 
acid (ATRA) for 1 week. ATRA was then 
removed and the cells were exposed to 
GRM supplemented with 20 ng/ml EGF for 
25 days. At day 28, the spheres were plated 
in Petri dishes coated with 1:30 Matrigel for 
1 week and cultured on GRM supplemented 
with 20ng/ml EGF. For terminal 
differentiation, at day 35, oligodendrocyte 
precursor cells (OPCs) were seeded on 
poly-L-lysine and human laminin (Sigma, 
MO) coated slides. At days 0 and 35, the 
cells were incubated under hypoxic 
conditions (1% O2) in the In vivo2 400 
chamber (Ruskinn Life Sciences) for 72 hrs 
with 500 nM FM19G11 or its DMSO 
vehicle as control. Then, the cells were 
harvested for total RNA or 
immunocytochemical staining.  
hESC culture 
Primary hESC colonies from the H9 line 
(WiCell Inc., Madison, USA) were cultured 
as described elsewhere (24). Briefly, hESC 
were mechanically dispersed into several 
small clumps and cultured on fresh, 
commercially available human foreskin 
fibroblasts (American Type Culture 
Collection, Manassas, VA, USA), 
inactivated by mitomycin C in ES medium 
containing Knockout-DMEM, 1 mM L-
glutamine, 100 mM non-essential amino 
acids, 20% serum replacement, 1% 
penicillin/Streptomycin, 8 ng/ml bFGF 
(Invitrogen, USA) and 100 mM ß-
mercaptoethanol (Sigma, USA). ES 
medium was changed every second day. 
Human embryonic stem cells were 
passaged by mechanical dissociation and 
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then removed to a freshly prepared human 
foreskin fibroblast layer. 
RNA isolation, semi and quantitative RT-
PCR 
One microgram of total RNA, extracted by 
using the RNeasy Mini-kit (Qiagen, 
Germany), was reverse-transcribed (RT) in 
a total reaction volume of 50 μl by means 
of incubation at 42°C for 30 min using 
random hexamer primers. The primer 
sequences for semiquantitative PCR are 
detailed in Supplementary data II. The 
target gene value was normalized to the 
expression of an endogenous reference 
(GAPDH).  
For quantitative PCR, mRNAs were 
amplified and quantified by SYBR Green 
or TaqMan probes (Applied Biosystems, 
CA, USA; Supplementary data II). As 
template, 40 ng of cDNA from target and 
housekeeping gene (GAPDH) were 
prepared in separate tubes for each primer 
master mix reaction. The comparative 
threshold cycle (CT) method was used to 
calculate the relative expression (25).  
DNA micro-array Analysis 
epSPC isolation and DNA micro-array 
hybridization was performed as described 
elsewhere (23).  
The gene profile was sorted by differential 
expression levels between the two 
experimental conditions (epSPC 48 h in 
hypoxia with FM19G11 versus DMSO) and 
clustered into biological functional profiles 
by FatiGO application (26). 
Western blot analysis 
Cells were collected and washed with cold 
PBS. Total cell protein extracts were 
isolated by use of 2% SDS-TrisCl lysis 
buffer plus proteinase inhibitors. Sub-
cellular fractionation was performed in two 
steps, by using hypotonic and hypertonic 
buffers for cytoplasm and nuclear fraction 
isolation, respectively. SDS-PAGE and 
hybridization steps were carried out as 
previously described (23), with antibodies 
against HIF1α (a kind gift from Dr. Berra), 
HIF2 α, PHD3, Sox2, Oct4, Notch1 
(Abcam, UK), RIP, NG2, Nestin and GFAP 
(Chemicon, USA) at 1:1000 dilution. β-
actin at 1:5000 dilution (Sigma, St. Louis, 
MO, USA) was used as loading control. 
The resulting bands were densitometrically 
analyzed by ImageJ software.  
Immunocytochemistry  
Fixed and permeabilized cells (0.05% 
Triton X-100), after blocking (1% fetal 
bovine serum), were incubated overnight at 
4ºC with the primary mouse antibodies 
(1:200), α-RIP, α-O4 (Chemicon, USA), α-
Hif-1α (BD, USA), and rabbit ones, α-NG2 
(Chemicon, USA) and α-Sox2 (Abcam, 
UK). For detection, Texas Red dye 
conjugated goat anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories, USA) and 
Oregon Green 488 goat antimouse IgG at 
1:400 (Invitrogen, CA, USA) were used. 
Signals were viewed by Confocal 
Microscopy (Leica). 
RNA interference by small interfering 
RNA (siRNA) duplex transfection for 
HIF1α and HIF2α 
Annealed siRNA duplexes were purchased 
from Applied Biosystems. The siRNA 
sequences targeting rat HIF1α (Acc. No. 
NM_0243591.1) and HIF2α (Acc. No. 
NM_023090.1) corresponded to the Cat. 
Nos. 4390816_s131713 and 
4390816_s131443, respectively (Applied 
Biosystems, UK).  500 nM of siRNA were 
used for transfection.  
ChIP analysis 
Chromatin immunoprecipitation analysis 
used LowCell ChIP Kit (Diagenode, USA), 
in line with manufacturer’s instructions, as 
described elsewhere (27). Samples were 
incubated with 10 µg of anti-HIF2α or 
AcH3 antibodies (Abcam, UK). An isotype-
matched antibody was used as control for 
non-specific binding. Rat Sox2 promoter 
region was analyzed in silico by using the 
Genomatix bioinformatics software portal.  
Statistical analysis 
Statistical comparisons were assessed by 
the Student’s t-test. All p values were 
derived from a two-tailed statistical test 
using the SPSS 11.5 Software. A p-value 
<0.05 was considered statistically 
significant.  
 
RESULTS 
FM19G11, a new HIFα  inhibitor  
To identify novel molecules targeting HIF 
pathway, we used a stable luciferase 
reporter gene-based screen containing 9 
repetitions of the HIF Responsive Element 
(HRE) 5´ upstream of the start codon in the 
active promoter region constitutively 
expressed in the HeLa cell line (HeLa-9x-
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HRE-Luc). These cells displayed more than 
100-fold higher luciferase activity after 
incubation in hypoxia (1% O2). We tested 
the HeLa-9x-HRE-Luc screen against a 
compound bank, containing more than 
12,000 compounds, chosen as 
representatives of the total chemical space. 
FM19G11 reduced hypoxia-induced 
luciferase activity by 50% (IC50) at 80 ± 5 
nM concentration (Figure 1A, inset). 
FM19G11 showed significant relative 
luciferase unit (RLU) inhibition from 30 
nM, with steady reduction in a 
characteristic dose-dependent manner 
(Figure 1A) and reaching 80% inhibition at 
1 µM (Figure 1B). To test the specificity of 
FM19G11 for HRE binding sites, we 
reproduced the luciferase-reporter gene 
assay by stable over-expression of CRE or 
TRE reporter constructs. ATF2 and JunB 
transient over-expression was used to 
induce CRE-mediated reporter gene 
activity; and c-fos and c-jun over-
expression, for TRE induction (Figure 1B, 
inset). No significant RLU inhibition of 
TRE or CRE transcriptional activity was 
found in the presence of any tested 
concentration of FM19G11 (Figure 1B). It 
is worth mentioning that no cytotoxicity for 
concentrations of FM19G11 lower than 30 
µM, in standard oxygen tension, or 50 µM, 
under hypoxic conditions, was observed on 
the HeLa cell line (Supplementary Figure 
1).  
Chemical synthesis of FM19G11 
The FM19G11 compound was chemically 
re-synthesized for extensive evaluation. As 
shown in Figure 1C, reaction of 2,4-
dinitrobenzoic acid with methyl 3-
aminobenzoate was followed by methyl 
ester hydrolysis and coupling with 
(bromomethyl)p-tolylketone to afford the 
target compound. FM19G11 was purified 
by flash column chromatography. 
FM19G11 inhibits HIFα proteins in 
human tumor cell lines 
We evaluated the effect of FM19G11 on 
total protein levels and on nuclear and 
cytoplasm fractionated extracts of HIF1α 
and 2α (Figure 1D and F), as well as the 
effect on the expression of their target 
genes PHD3 (Figure 1D) and VEGF 
(Figure 1E) in the HeLa cell line. 
Simultaneous incubation at 300 nM of 
FM19G11 from 1 to 12 hours of hypoxia 
exposure (1% O2) prevented HIF1α and 
HIF2α accumulation (this effect was 
extended to 24 h for HIF1α accumulation). 
Although most HIFα protein was found in 
the nucleus in all cases, a detectable amount 
of both isoforms (1 and 2α) was found in 
the cytosolic fraction in the presence of 
FM19G11 after 4 h of incubation at 1% O2. 
However, no significant changes in the sub-
cellular location of HIFα proteins were 
observed at any other tested time (Figure 
1F). The prolyl hydroxylases 
(PHDs/EGLNs) are the central regulators of 
the molecular responses to oxygen 
availability (28) and PHD3 is also directly 
regulated by both α proteins (29). 
FM19G11 significantly inhibited PHD3 
protein levels (Figure 1D). In addition, the 
hypoxic transcriptional induction of VEGF, 
a well-known target gene of HIF α proteins 
(30) was significantly blocked by all tested 
doses of FM19G11 (Figure 1E). Because 
HIF promoter region contains multiple 
HRE, indicating a self-regulating 
mechanism (31), we also analyzed both 
HIFα isoforms at the mRNA levels in the 
presence of FM19G11. The hypoxia-
dependent induction of HIF1 and 2α 
mRNA was significantly lower in the 
presence of FM19G11 after 6 hours of 
incubation (data not shown), coinciding 
with the significant reduction of the protein 
levels induced by the compound. However, 
no significant changes in protein levels, in 
comparison with vehicle-treated cells, were 
obtained at shorter (1 or 3 hours) or longer 
(9 or 12h) hypoxic exposition times (data 
not shown).  
To investigate whether HIF1α protein 
inhibition by FM19G11 was mediated by 
promoting the activation of the proteasomal 
system, we performed an experiment in the 
presence of the proteasomal inhibitor 
MG132 in normoxia. Interestingly, MG132 
did not affect any isoform, HIF1 or 2α 
accumulation by FM19G11, suggesting a 
proteasome-independent mechanism on 
HIFα inhibition (data not shown). The 
action of FM19G11 on HIFα proteins was 
not restricted to HeLa cells, since it was 
also observed in adult human cell lines 
derived from various tissue types, including 
colon HT-29 and the breast cancer cell line 
MDA-MB-435-S (data not shown).  
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FM19G11 inhibits HIFα protein 
accumulation in adult and embryonic stem 
cells from rodents and humans, 
respectively. 
Interestingly, the compound FM19G11 had 
a similar effect on HIF regulation in stem 
cells. We analyzed the effect of the 
compound on adult rat ependymal 
stem/progenitor cells (epSPC) and on 
human embryonic stem cells (hESC). 
Figure 1G shows the dose-dependent 
inhibitory effect of FM19G11 on both 
HIFα proteins in epSPC. Transcriptional 
repression of PHD3 was also observed in 
the rat epSPC (Figure 1H) and in hESC 
(data not shown) treated with 500 nM of 
FM19G11 for 48 hrs under hypoxia.  
FM19G11 regulates Oct4 and Sox2 
pluripotency markers  
HIF2α transcription factor directly 
regulates the expression of Oct4, indicating 
a function of this HIF protein in the self-
renewal and differentiation of stem cell 
properties (8). We observed by real-time 
PCR that FM19G11 abrogates the 
increment associated with hypoxia of the 
transcriptional expression of Oct4 in both 
tested stem cell types, rat epSPC (Figure 
2A and B) and human ESC (Figure 2C). In 
confirmation of recently published results 
(32),  this transcriptional inhibition of Oct4 
by FM19G11 was observed in parallel with 
the down-regulation in both stem cell types 
of Sox2, another important player in 
stemness maintenance (33) (Figure 2). In 
addition, epSPC treated with FM19G11 
under hypoxia showed lower mRNA levels 
of TGFα and Nanog, target genes of Oct4 
and Sox2, respectively (Figure 2 A, lower 
panel). The regulation of the two proteins, 
Oct4 and Sox2, by the compound showed a 
dose-dependent inhibitory pattern. The time 
and dose-response experiments carried out 
indicated that the hypoxia-induced 
expression of Oct4 and Sox2 was more 
efficiently reduced at 500 nM of FM19G11 
after 48 hrs in 1% O2 (Figure 2B, upper and 
left panel). The immunocytochemical 
studies confirmed the diminished 
expression of Sox2 in cells treated with 
FM19G11, with no apparent alterations in 
protein location (Figure 2B and C) in 
relation to the controls. 
HIF2α regulates Sox2 expression  
The role of Sox2 in pluripotency is mostly 
based on its function of maintaining Oct4 
levels and the consequent expression of 
many pluripotency-associated genes, e.g. 
Fgf4, Lefty1, Nanog, which are tightly 
regulated by an enhancer containing Oct4 
and Sox2 binding motifs (18). Oct4 are 
reported to be a direct target of HIF2α (8). 
Recently McCord et al., using the siRNA 
approach, reported for the first time 
experimental evidence indicating that Sox2 
have HIF-dependent regulation (32). Here, 
we validated these results, by using specific 
siRNA oligos, the knock-down expression 
of HIF2α, but not of HIF1α, that blocks 
hypoxia-induced expression of both Oct4 
and Sox2 in epSPC (Figure 3A). These 
results strongly indicate the direct 
involvement of HIF2α in the positive 
regulation of both pluripotency markers, 
Oct4 and Sox2. However, to provide further 
and new data that may indicate the direct 
connection between HIF2α and Sox2 
regulation, we searched for putative HRE-
binding sequences within the promoter 
region of rodent Sox2 gene. The in silico-
predicted occupancy of HIF for HRE 
binding sites, over 5kb promoter region 
immediately upstream of the transcription 
start signal of Sox2, was first analyzed by a 
reporter-based screen including the 
promoter sequence containing two HRE 
sites (pGL3-mpSox2) and after the 
performance of point mutation (pGL3-
mpSox2Δ) to inactivate both sites. 
Transcriptional activation under hypoxia, 
by using the wild-type sequence (pGL3-
mpSox2) rather than the empty vector, was 
significantly abolished by using the mutated 
sequence (pGL3-mpSox2Δ; Figure 3B).  
Finally, to disclose a specific role for 
HIF2α in the Sox2 promoter activity 
depending on HRE activation, a chromatin 
immunoprecipitation assay (ChIP) was 
performed. The specific ChIP signals 
obtained after immunoprecipitation with 
anti-HIF2α antibody showed, first, more 
amplified immunoprecipitated sequences 
after hypoxia stimulation and, then, reduced 
binding of HIF2α within the Sox2 promoter 
when epSPC were treated with FM19G11 
(Figure 3C). 
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Epigenetic influences on FM19G11-
dependent Sox2 regulation  
To reveal the extended mechanism involved 
in FM19G11-dependent regulation of Sox2 
expression, we performed a DNA-
microarray analysis, comparing the gene 
expression profile of epSPC when treated 
under hypoxia with the compound 
FM19G11 or its vehicle. The differentially 
expressed genes were organized according 
to Gene Ontology (GO) by using the 
corresponding gene-GO association table to 
obtain FatiGO-implemented analysis. As 
shown in Figure 3D or in Supplementary 
Figure 2 (for more details), two main 
groups after biological function clustering 
were over-represented in the presence of 
FM19G11. The first group was related to 
chromatin assembly; and the second, to 
transcriptional regulation. Taken together, 
they may indicate that FM19G11 activity in 
transcriptional regulation is mediated 
throughout alteration of epigenetic events 
by chromatin modifications. Stabilized 
HIFα proteins bind with ARNT subunit and 
recruit the p300/CBP complex, two 
coactivators with histone acetyltransferase 
activity (34). Based on the transcription 
profile obtained in the presence of the 
FM19G11, we tested whether FM19G11 
would behave as a histone deacetylase 
inhibitor, but no positive results were 
obtained (data not shown). However, the 
presence of FM19G11 inhibited the 
hypoxia-induced expression levels of the 
Histone 3 acetylated form (AcH3), as well 
as the levels of total p300, which act as 
acetyl transferase (Figure 3E). These results 
were obtained in close association with the 
repression of HIF targets, including the 
pluripotency markers. Furthermore, the 
ChIP signals obtained after 
immunoprecipitation with anti-AcH3 
antibody revealed a rich acetylated region 
in the Sox2 promoter when the epSPC were 
exposed to hypoxia. In contrast, a 
significant reduction in AcH3 signals was 
seen in epSPC maintained under hypoxic 
conditions when FM19G11 was present 
(Figure 3F).    
FM19G11 promotes oligodendrocyte 
differentiation under hypoxia  
Hypoxia blocks stem cell differentiation; 
and HIF expression is widely accepted to be 
associated with stemness. Here, we showed 
the effect of FM19G11 - an HIFα inhibitor 
- on oligodendrocyte differentiation under 
hypoxia. An oligodendrocyte differentiation 
protocol from undifferentiated epSPC was 
induced till day 42, in line with our earlier 
research (23), by following the steps 
described in Figure 4A. The process of 
differentiation with epSPC occurred in 
parallel, in the presence and absence of 
FM19G11, in an atmosphere of 1% O2  and 
for early and late differentiation stages from 
day 1 to day 3 and from day 35 to day 37, 
respectively (Figure 4). At both stages, the 
hypoxic conditions blocked the 
differentiation process, according to the cell 
markers RIP and NG2 at early stage (day 1-
3) and the mature oligodendrocyte markers 
04 and RIP at late stage (day 35-37) (Figure 
4B; and 4C for RIP expression). In all 
cases, the addition of FM19G11 rescued the 
expression of the above-mentioned cell 
markers (Figure 4B; and 4C for RIP 
expression). It is also important to mention 
the poor migration from the epSPC 
neurospheres into the matrix, under low 
oxygen concentration and at an early stage 
of the differentiation protocol (Figure 4B). 
At day 37, the cells were also harvested for 
RT-PCR and Western blot analysis (Figure 
4C). From day 35 of the differentiation 
protocol, the precursors were forced to a 
definitive maturation by culturing in a 
laminin matrix (Figure 4A). Sox2, Oct4, 
Notch1 and Nestin, typically expressed in 
undifferentiated progenitor cells, were at 
this late stage up-regulated in hypoxia, in 
comparison with normoxic conditions 
(Figure 4C). Olig2 and Nkx2.2, 
homeodomain transcription factors, are 
linked to oligodendrocyte early 
specification during spinal cord 
development, gradually reducing in mature 
cells. The exposure to low oxygen 
concentration induced the expression of 
these early specific oligodendrocyte 
markers, Olig2 and Nkx2.2 (Figure 4C), but 
in the presence of FM19G11 the cells 
recovered the low expression levels of these 
transcription factors at late differentiation 
stage. The expression of the astrocytic 
marker GFAP diminished from day 3 of the 
differentiation protocol after ATRA 
addition (23). Hypoxia significantly 
induced the expression of GFAP, indicating 
lower oligodendrocyte specification in the 
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epSPC culture. This induction was 
abolished by FM19G11 treatment (Figure 
4C). Considering all above, the hypoxia-
induced delay in directed oligodendrocyte 
differentiation was aborted by FM19G11 
treatment. 
 
DISCUSSION 
Over the last 20 years, major efforts have 
gone into the search for HIFα inhibitors for 
use in new drugs (35). Though a wide range 
of diverse molecules have been found to 
inhibit the HIF pathway, these molecules 
often have other actions that indirectly 
cause lower HIF protein levels. At present, 
none of the reported HIF inhibitors have 
met the pharmacokinetic requirements for 
human therapeutic use. Here we 
demonstrate that the new chemical entity 
FM19G11 acts as a potent inhibitor of 
HIFα proteins in hypoxia, giving high 
selectivity against other transcription 
factors of the AP-1 complex used during 
the screening campaign. Furthermore, we 
show that this molecule represses the target 
genes of both HIF proteins, 1α and 2α, in 
cancer cell lines -- of various tissues -- 
showing lower transcript and protein levels 
in rat epSPC and human ESC, which 
suggests a steady mechanism of action for 
this new drug. The complete eradication of 
what are known as cancer stem cells might 
be crucial in curing cancer; reduction of 
HIF activity may promote their 
differentiation and decrease their ability to 
repopulate tumors after chemo- and radio-
therapy (6,36). The low toxicity of this 
small molecule -- no cytotoxicity was 
observed at concentrations a thousand times 
higher than the IC50 even in hypoxic 
atmosphere -- permitted its safe use in a 
wide variety of live-cell assays, including 
immuno-based determinations and long-
lasting experiments in stem cell 
differentiation.  
Although hypoxia is widely linked to many 
pathological procedures (1-3), it is also a 
controller of major physiological processes, 
such as differentiation status during 
embryogenesis and in adulthood (1,6,8). 
Hypoxia is associated with the 
undifferentiated status of stem cells; and the 
function of HIFα proteins in maintaining 
multipotency was only found quite recently. 
The real mechanisms by which the HIF 
pathway interacts with other pathways to 
keep stemness are still largely unknown, 
despite a great many publications in the last 
few years (6,36). First, HIF1α was shown 
to block neuronal and myogenic 
differentiation in a Notch-dependent 
manner (5) and, more recently, Oct4 was 
identified as a HIF2α-specific target gene 
(8) controlled by Sox2 (18). First of all, 
Keith and Simon elegantly hypothesized 
that Sox2 and Klf4 might also be HIF 
targets (36) and recently McCord et al. 
validated this hypothesis based on the 
inhibition by a siRNA of the 2α isoform 
(32). However McCord et al. do not show 
whether Sox2 is solely under the control of 
HIF2α or if there is an overlap with the 1α 
isoform. A reporter assay, based on the 
promoter region of Sox2 containing two 
HRE sites, a HIF2α chromatin 
immunoprecipitation (ChIP) experiment 
and the use of siRNAi experiments leading 
to HIF2α-knock-down cells strongly 
demonstrated that Sox2 is a direct target of 
the HIFα proteins, and, in particular, that its 
regulation resides specifically in the 2α 
isoform. Complementary information that 
reinforces the role of HIF2α in the direct 
control of Sox2 was provided by the ChIP 
experiments carried out in the presence of 
the inhibitor FM19G11. All the above 
clearly pointed to the utility of this small 
molecule, at present seen just as a tool 
compound, to clarify the hierarchy of 
HIF2α in the control of two of the key 
genetic factors that govern pluripotency.  
Microenvironment influence on chromatin 
assembly and on the accessibility and/or 
dynamic interplay of certain transcription 
factors determines stem cell differentiating 
status (27,37-39). In fact, the Oct4 locus 
adopts a closed conformation in 
differentiating embryonic somatic cells, 
making it refractory to regulation by 
HIF2α (8). Here, we confirmed the direct 
association between the HIF2α-positive 
transcriptional regulation of Sox2 and the 
open chromatin conformation of its 
promoter. FM19G11 prevented the general 
H3 acetylation induced by hypoxia in 
epSPC and reduced the expression of p300, 
the main co-activator for transcriptional 
activation of HIFα proteins with histone 
acetyltransferase activity. ChIP analysis by 
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AcH3 immuno-precipitation showed direct 
involvement of the acetylation mechanism 
in hypoxia and FM19G11 regulation over 
Sox2 transcriptional activity. Although 
p300 immunoprecipitation experiments 
proved a Sox2 interaction (unpublished 
data), no evidence linking Sox2 and p300 
transcriptional regulation on maintaining 
the undifferentiated stage was found, as was 
previously described in the case of  Notch1 
(40). The inhibitory activity of FM19G11 
on Oct4 and Sox2, Notch, Nanog and TGF-
alpha opened up new approaches to its use 
in cell reprogramming experiments with 
neural progenitor cells for the SCI 
regeneration model in rat. Therefore, loss of 
myelinating oligodendrocytes or 
oligodendrocyte progenitor cells (OPC) is a 
feature of many CNS injury and disease 
states. Moreover, due to secondary damage 
after SCI, the ischemic environment does 
not allow re-myelinization, partly because 
there is an arrest of oligodendrocyte lineage 
maturation (41). Indeed, when 
undifferentiated progenitors are 
transplanted into an ischemic environment, 
no significant cell differentiation occurs 
(23,42). The cell fate modulation of 
transplanted or endogenous stem cells by 
forcing the generation of oligodendrocytes 
to re-myelinate spared axons in the vicinity 
of the lesion would be a powerful 
therapeutic approach for SCI regeneration 
(23,43,44). As mentioned above, FM19G11 
did repress a variety of key genes involved 
in stemness and our reprogramming 
experiments showed that the inhibitor 
favors oligodendrocyte differentiation, 
possibly through the modulation of Sox2 
and Oct4 expression and by allowing neural 
stem and/or precursor cells to differentiate. 
Sox-2 was shown to be the key player in 
cell fate control, regulating Oct4 and, 
combined with a few other factors (c-myc 
and/or Klf4), confers ES-like properties on 
mature murine fibroblasts (20). However, 
given the results reported here, it should be 
emphasized that HIF2α is now positioned 
in the upper hierarchy of cell fate. All in all, 
the low toxicity profile of this drug favors 
pharmacological approaches and enables it 
to act on SCI regeneration in rigorously 
defined models. 
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FIGURE LEGENDS 
 
Figure 1. Synthesis and analysis of FM19G11 activity in HIFα proteins and their target 
genes under hypoxia. A) HeLa-9x-HRE-Luc cells treated with different concentrations of 
FM19G11 (0-0.5 µM) were exposed to 1% O2 for 6h.  FM19G11 inhibits in a dose-responsive 
way HIF-translational activity in the luciferase reporter assay. Inset: Calculation of CI50 by 
converting the RLU (relative luciferase units) into % of RLU inhibition. B) 293-TRE or 293-
CRE, transiently over-expressing c-fos and c-jun or ATF2 and JunB, respectively, were treated 
with FM19G11 0.3 µM for Western blot analysis (inset) or with 0-1 µM for 6 h in the luciferase 
reporter assay. Luciferase activity in vehicle-treated cells was taken as 0% of inhibition. C)  
Chemical synthesis of FM19G11 in three steps. The reaction of 2,4-dinitrobenzoic acid with 
methyl 3-aminobenzoate was followed by methyl ester hydrolysis and coupling with 
(bromomethyl)p-tolylketone to form the target compound. D) Intracellular levels of HIF1 and 
2α and PHD3 proteins were assayed after HeLa exposition to 1% O2 for 1-24 h with FM19G11 
300 nM (+) or its vehicle (-). 24 h exposition at 20% O2 in the absence of FM19G11 (-) was 
taken as basal condition. ß-actin served as loading control. The graphs represent the mean of 
absolute densitometry values of each condition from three independent experiments. E) 
TaqMan® Real Time PCR analysis of VEGF in HeLa cells treated for 6 h with FM19G11 (0-
300 nM) at 20% or 1% O2. F) left panel: Representative example of nuclear (n) and cytoplasm 
(c) fractionated cell proteins assayed for HIFα protein expression. HeLa cells were treated with 
FM19G11 300 nM (+) or its vehicle (-) for 4-9 h at 20% or 1% O2. Right panel: 
Immunostaining for HIF1α of HeLa cells treated with FM19G11 or its vehicle (DMSO) under 
hypoxia for 6 hs. G) epSPC: upper panel: Representative experiment of FM19G11 dose-
response, showing the effect on HIFα protein expression after 48 h in hypoxia (1% O2). Lower 
panel: mean of densitometry values of HIFα protein expression analysis. Values are shown as a 
percentage of the control (20% O2). H) epSPC: TaqMan® Real Time PCR analysis of PHD3 
relative expression levels with vehicle or FM19G11 (500 nM) treated for 48 hours under 
normoxia (20% O2) or hypoxia (1% O2). Results were standardized by the housekeeping gene 
GAPDH. mRNA levels were calculated by the 2-ΔΔCT  method.  
Results were obtained from three independent experiments. *p<0.05 versus 20% O2), § p<0.05 
versus vehicle at 1% O2 determined by Student’s t test.   
 
Figure 2. FM19G11 regulates Oct4 and Sox2 pluripotency markers in rodent and human 
stem cells. epSPC (A and B) and hESC (C). A) Upper panel: Real Time-SYBR Green PCR 
analysis of rat Sox2 and Oct4 relative expression levels. Lower Panel: Semi-quantitative PCR 
of Oct4, Sox2 and their direct target genes, Tgfα and Nanog, respectively. Cells were incubated 
with 500 nM FM19G11 (+) or its vehicle (-) for 48 h under hypoxia (1% O2). 20% O2 was taken 
as basal condition. GAPDH served as a loading control. B) Left panels: Representative Western 
blot (upper panels) and densitometry analysis of three independent experiments (lower panels). 
FM19G11 dose-dependent effect on Oct4 and Sox2 protein expression after 48 h of hypoxia 
exposure. Values are shown as a percentage of the control (20% O2). Right panels: 
Representative immunostaining of Sox2 protein in undifferentiated neurospheres treated for 48 
h in 1% O2 with vehicle or 500 nM FM19G11. C) Left panel: TaqMan® Real Time PCR 
analysis of human Sox2 and Oct4 relative expression levels in hESC treated with 500 nM 
FM19G11 or its vehicle; Right panel: Qualitative immunostaining analysis of human Sox2 
protein expression in undifferentiated hESC colonies treated for 48 h in 1% O2 with DMSO 
(vehicle) or 500 nM FM19G11. 20% O2 condition served as basal control. Results were 
obtained from three independent experiments. *p<0.05 versus 20% O2), § p<0.05 versus vehicle 
at 1% O2, determined by Student’s t test.   
 
Figure 3. Hif2α regulates Sox2 expression and influences the epigenetic mechanisms.  A) 
epSPC were exposed to 20% O2 or 1% O2 for 48 h. 500 nM of each siRNA duplex, scramble 
(Scr, non-specific probe), HIF1α or HIF2α specific rat probes were transfected 24 h before 
oxygen-dependent stimulation. Western blot assay showed that only HIF2α knock-down also 
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reduced the protein levels of Sox2 and Oct4. ß-actin served as a loading control. * (when 
compared with scramble at 20% O2), § (when compared with scramble at 1% O2), p<0.05 was 
determined by Student’s t test. B) ChIP analysis within rat Sox2 promoter. There were a 
significantly higher number of copies of Sox2 promoter by Real Time PCR amplification after 
chromatin immunoprecipitation assays using specific antibody for HIF2α. The presence of 
FM19G11 significantly inhibited hypoxia-dependent induction. *p<0.05 versus 20% O2), § 
p<0.05 versus vehicle at 1% O2 determined by Student’s t test. C) Luciferase reporter assay 
under hypoxia for 6 h.  HEK293T cells transiently transfected with pGL3-basic, empty vector, 
including the wild-type mouse Sox2 promoter sequence (pGL3-mpSox2) or point-mutated at 
both HRE sites (pGL3-mpSox2Δ) (see diagram on the right) 24 hs before hypoxic stimulus. D) 
FatiGO analysis of epSPC treated with 500 nM FM19G11 was compared with vehicle alone for 
48h in hypoxia. Two biological functional groups were over-represented in FM19G11-treated 
sample after hierarchical clustering. E) left panel: Representative Western blot assay for epSPC 
treated (+) or not (-) with FM19G11 500 nM, exposed for 48 h at 20% or 1% O2; right panel: 
densitometry analysis of three independent experiments. F) ChIP analysis within rat Sox2 
promoter by using AcH3 antibody for chromatin immunoprecipitation. * (vs 20% O2), § (vs 
vehicle at 1% O2), p<0.05 was determined by Student’s t test.    
 
Figure 4. FM19G11 favors oligodendrocyte cell differentiation of epSPC under hypoxia. 
A) Diagram of differentiation protocol. B) Immunostaining assay for oligodendrocyte cell 
markers: RIP and NG2 (upper panels) and O4 (lower panels). Upper panels, cells treated with 
500 nM FM19G11 or DMSO (vehicle) from day 1 to day 3 of the differentiation protocol; lower 
panels, cells treated during day 35 to day 37 of the differentiation protocol under both normoxic 
(20% O2) and hypoxic (1% O2) conditions. C) Extended analysis at day 37 of the differentiation 
process. epSPC were cultured under normoxic (20% O2) and hypoxic (1% O2) atmospheres and 
treated with FM19G11 500 nM (+) and vehicle alone (-). The undifferentiated stage (Oct4, 
Sox2, Olig2, Nkx2.2, Notch1, Nestin, GFAP) and the oligodendrocyte specific fate cell marker 
(RIP) were assayed by Western blot (right panel) and/or PCR (left panel). 18S and ß-actin 
expression served as loading controls for PCR and Western blot, respectively.  
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